RE:WarrantsI just look at COV as having 20M shares fully diluted; but even at that COV has a trailing P/E of less than 10 and a very bright outlook for growth with Molnlycke just beginning to market Mepitel Film AM and Mepitel Film IV AM. I don't see any other stock offering nearly as good of a value in the advanced woundcare space (ie.: ALQA, DSCI, MDWD, etc..). I know all of those are U.S. listed companies, but considering Abe and Brian got a dual listing for their prior company, Cedara Software, I wouldn't rule out a similar move here in the future when the time is right.